Tenofovir amibufenamide: A potential alternative for chronic hepatitis B treatment.

Tenofovir amibufenamide (TMF) is a novel prodrug of tenofovir that demonstrates a promising safety and efficacy profile. A recent study by Peng compared TMF with tenofovir alafenamide in the treatment of chronic hepatitis B. The findings indicated that both medications offer similar efficacy in terms of viral response and alanine aminotransferase normalization. Notably, TMF showed potential advantages in lipid management, as it did not significantly affect cholesterol levels, unlike tenofovir alafenamide. This correspondence highlights the need for further research to evaluate the long-term safety and efficacy of TMF, its impact on cardiovascular risk, and its use in specific patient populations.